Targeting gliomas with STAT3-silencing nanoparticles

Padma Kadiyala; Jason V Gregory; Pedro R Lowenstein; Joerg Lahann; Maria G Castro

doi:10.1080/23723556.2020.1870647

Targeting gliomas with STAT3-silencing nanoparticles

Mol Cell Oncol. 2021 Jan 31;8(2):1870647. doi: 10.1080/23723556.2020.1870647.

Authors

Padma Kadiyala^{1

2}, Jason V Gregory^{3

4}, Pedro R Lowenstein^{1

2

3}, Joerg Lahann^{3

4

5}, Maria G Castro^{1

2

3}

Affiliations

¹ Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
² Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA.
³ Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
⁴ Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.
⁵ Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.

Abstract

Glioblastoma is an aggressive brain tumor with poor prognosis. The brain is protected by the blood-brain barrier, which precludes transport of chemotherapeutics. We developed nanoparticles that achieve delivery of small-interfering RNA against Stat3 after systemic administration. Nanoparticles combined with radiation inhibited tumor progression and elicited anti-glioblastoma immunity in mice.

Keywords: Glioma; nanoparticles; immunotherapy; systemic drug-delivery; targeted-therapy.

Abstract

Grants and funding